StreetInsider.com News Articles

Enanta Pharmaceuticals sets up $75M at-the-market stock offering

Thu, 02 Jul 2026 16:58:26 -0400

Enanta Pharmaceuticals (NASDAQ: ENTA) has entered into an open market sale agreement with Jefferies LLC, dated July 2, 2026, to sell up to $75,000,000 worth of common stock through an at-the-market offering.

Under the terms of the agreement, Enanta may offer and sell shares of its common stock, with a par value of $0.01 per share, from time to time through Jefferies acting as sales agent. Jefferies will receive a commission of up to 3.0% of gross proceeds from any shares sold under the agreement.

Jefferies is not required to sell any specific number or dollar amount of shares and will act

Form 8-K ENANTA PHARMACEUTICALS For: Jul 02

Thu, 02 Jul 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260702/26729078.html

Form 8-K ENANTA PHARMACEUTICALS For: Jul 02

Thu, 02 Jul 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260702/26729078.html

Form 424B5 ENANTA PHARMACEUTICALS

Thu, 02 Jul 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260702/26729033.html

Form 424B5 ENANTA PHARMACEUTICALS

Thu, 02 Jul 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260702/26729033.html

Enanta Pharma loses appeal in Pfizer Paxlovid patent case

Tue, 23 Jun 2026 17:30:49 -0400

Enanta Pharmaceuticals (NASDAQ: ENTA) lost its patent infringement appeal against Pfizer Inc. after the United States Court of Appeals for the Federal Circuit ruled on June 23, 2026, that the claims of U.S. Patent No. 11,358,953 were invalid.

The Federal Circuit's decision affirmed a December 2024 summary judgment ruling by the United States District Court for the District of Massachusetts. Enanta had filed the appeal seeking damages for alleged infringement related to the manufacture, use, and sale of Pfizer's COVID-19 antiviral Paxlovid (nirmatrelvir tablets; ritonavir tablets).

Enanta Pharma loses appeal in Pfizer Paxlovid patent case

Tue, 23 Jun 2026 17:30:49 -0400

Enanta Pharma loses appeal in Pfizer Paxlovid patent case

Tue, 23 Jun 2026 17:30:49 -0400

Enanta Pharma loses appeal in Pfizer Paxlovid patent case

Tue, 23 Jun 2026 17:30:49 -0400

Form 8-K ENANTA PHARMACEUTICALS For: Jun 23

Tue, 23 Jun 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260623/26680696.html

Form 8-K ENANTA PHARMACEUTICALS For: Jun 23

Tue, 23 Jun 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260623/26680696.html

H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA)

Tue, 23 Jun 2026 06:52:25 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $20.00 price target on Enanta Pharmaceuticals (NASDAQ: ENTA).

The analyst commented: "We view Enanta's recent FDA alignment on zelicapavir as an important positive development that meaningfully reduces regulatory uncertainty and establishes a clear path toward registration in RSV. Following discussions with the agency, the company received agreement to advance zelicapavir through a single Phase 2b/3 study in high-risk adult RSV patients rather than conducting two independent Phase 3 trials. In our view, the outcome compares favorably with investor expectations and reflects the strength of the efficacy signal observed in the previously

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus